Abstract
Automated closed-loop insulin delivery, also referred to as the 'artificial pancreas', has been an important but elusive goal of diabetes treatment for many decades. Research milestones include the conception of continuous glucose monitoring in the early 1960s, followed by the production of the first commercial hospital-based artificial pancreas in the late 1970s that combined intravenous glucose sensing and insulin delivery. In the past 10 years, research into the artificial pancreas has gained substantial momentum and focused on the subcutaneous route for glucose measurement and insulin delivery, which reflects technological advances in interstitial glucose monitoring and the increasing use of the continuous subcutaneous insulin infusion. This Review discusses the design of an artificial pancreas, its components and clinical results, as well as the advantages and disadvantages of different types of automated closed-loop systems and potential future advances. The introduction of the artificial pancreas into clinical practice will probably occur gradually, starting with simpler approaches, such as overnight control of blood glucose concentration and temporary pump shut-off, that are adapted to more complex situations, such as glycemic control during meals and exercise.
Key Points
-
Closed-loop systems deliver insulin according to real-time glucose levels
-
Closed-loop systems combine three components: a continuous glucose sensor, an insulin pump and a control algorithm
-
The subcutaneous route for glucose sensing and insulin delivery is most promising for widespread clinical use
-
Compared with conventional pump therapy, closed-loop insulin delivery under supervised conditions reduced the frequency of hypoglycemia and increased the time within the target glucose range
-
Introduction into clinical practice may be gradual, beginning with simpler approaches, such as overnight control and temporary pump shut-off, that progress to more complex situations, such as control during meals and exercise
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Steil, G. M., Panteleon, A. E. & Rebrin, K. Closed-loop insulin delivery-the path to physiological glucose control. Adv. Drug Deliv. Rev. 56, 125–144 (2004).
Renard, E., Costalat, G., Chevassus, H. & Bringer, J. Artificial beta-cell: clinical experience toward an implantable closed-loop insulin delivery system. Diabetes Metab. 32, 497–502 (2006).
Nishida, K., Shimoda, S., Ichinose, K., Araki, E. & Shichiri, M. What is artificial endocrine pancreas? Mechanism and history. World J. Gastroenterol. 15, 4105–4110 (2009).
Shichiri, M. Artificial endocrine pancreas: development and clinical applications (Kamome Press, Kumamoto, 2000).
Kumareswaran, K., Evans, M. L. & Hovorka, R. Artificial pancreas: an emerging approach to treat type 1 diabetes. Expert Rev. Med. Devices 6, 401–410 (2009).
Hovorka, R. The future of continuous glucose monitoring: closed loop. Curr. Diabetes Rev. 4, 269–279 (2008).
Hovorka, R. Continuous glucose monitoring and closed-loop systems. Diabet. Med. 23, 1–12 (2006).
Steil, G. M. & Rebrin, K. Closed-loop insulin delivery—what lies between where we are and where we are going? Expert Opin. Drug Deliv. 2, 353–362 (2005).
Smiley, D. & Umpierrez, G. E. Management of hyperglycemia in hospitalized patients. Ann. NY Acad. Sci. 1212, 1–11 (2010).
Eslami, S., Abu-Hanna, A., de Jonge, E. & de Keizer, N. F. Tight glycemic control and computerized decision-support systems: a systematic review. Intensive Care Med. 35, 1505–1517 (2009).
Hirsch, I. B. Clinical review: Realistic expectations and practical use of continuous glucose monitoring for the endocrinologist. J. Clin. Endocrinol. Metab. 94, 2232–2238 (2009).
De Block, C., Vertommen, J., Manuel-y-Keenoy, B. & Van Gaal, L. Minimally-invasive and non-invasive continuous glucose monitoring systems: indications, advantages, limitations and clinical aspects. Curr. Diabetes Rev. 4, 159–168 (2008).
Klonoff, D. C. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 28, 1231–1239 (2005).
Tamborlane, W. V. et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N. Engl. J. Med. 359, 1464–1476 (2008).
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 32, 1378–1383 (2009).
Pickup, J. & Keen, H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 25, 593–598 (2002).
Selam, J. L. CSII in Europe: where are we, where are we going? An analysis of articles published in Infusystems International. Diabetes Res. Clin. Pract. 74 (Suppl. 2), S123–S126 (2006).
Bequette, B. W. A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. Diabetes Technol. Ther. 7, 28–47 (2005).
Magni, L. et al. Model predictive control of type 1 diabetes: an in silico trial. J. Diabetes Sci. Technol. 1, 804–812 (2007).
Parker, R. S., Doyle, F. J. 3rd & Peppas, N. A. A model-based algorithm for blood glucose control in type I diabetic patients. IEEE Trans. Biomed. Eng. 46, 148–157 (1999).
Hovorka, R. et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol. Meas. 25, 905–920 (2004).
Albisser, A. M. et al. An artificial endocrine pancreas. Diabetes 23, 389–396 (1974).
Clemens, A. H. Feedback control dynamics for glucose controlled insulin infusion system. Med. Prog. Technol. 6, 91–98 (1979).
Marchetti, G., Barolo, M., Jovanovic, L., Zisser, H. & Seborg, D. E. An improved PID switching control strategy for type 1 diabetes. IEEE Trans. Biomed. Eng. 55, 857–865 (2008).
Castle, J. R. et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 33, 1282–1287 (2010).
Atlas, E., Nimri, R., Miller, S., Grunberg, E. A. & Phillip, M. MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care 33, 1072–1076 (2010).
El-Khatib, F. H., Jiang, J. & Damiano, E. R. Adaptive closed-loop control provides blood-glucose regulation using dual subcutaneous insulin and glucagon infusion in diabetic Swine. J. Diabetes Sci. Technol. 1, 181–192 (2007).
Rodríguez-Herrero, A. et al. A simulation study of an inverse controller for closed- and semiclosed-loop control in type 1 diabetes. Diabetes Technol. Ther. 12, 95–104 (2010).
Lee, H., Buckingham, B. A., Wilson, D. M. & Bequette, B. W. A closed-loop artificial pancreas using model predictive control and a sliding meal size estimator. J. Diabetes Sci. Technol. 3, 1082–1090 (2009).
Percival, M. W., Zisser, H., Jovanovic, L. & Doyle, F. J. 3rd. Closed-loop control and advisory mode evaluation of an artificial pancreatic Beta cell: use of proportional-integral-derivative equivalent model-based controllers. J. Diabetes Sci. Technol. 2, 636–644 (2008).
Dua, P., Doyle, F. J. 3rd & Pistikopoulos, E. N. Model-based blood glucose control for type 1 diabetes via parametric programming. IEEE Trans. Biomed. Eng. 53, 1478–1491 (2006).
Trajanoski, Z. & Wach, P. Neural predictive controller for insulin delivery using the subcutaneous route. IEEE Trans. Biomed. Eng. 45, 1122–1134 (1998).
de Leiva, A. et al. Telemedical artificial pancreas: PARIS (Pancreas Artificial Telemedico Inteligente) research project. Diabetes Care 32 (Suppl. 2), S211–S216 (2009).
Dassau, E., Jovanovic, L., Doyle, F. J. 3rd & Zisser, H. C. Enhanced 911/global position system wizard: a telemedicine application for the prevention of severe hypoglycemia—monitor, alert, and locate. J. Diabetes Sci. Technol. 3, 1501–1506 (2009).
Kovatchev, B. et al. Control to range for diabetes: functionality and modular architecture. J. Diabetes Sci. Technol. 3, 1058–1065 (2009).
Ellingsen, C. et al. Safety constraints in an artificial pancreatic beta cell: an implementation of model predictive control with insulin on board. J. Diabetes Sci. Technol. 3, 536–544 (2009).
Hovorka, R. et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 375, 743–751 (2010).
Elleri, D. et al. Suspended insulin infusion during overnight closed-loop glucose control in children and adolescents with type 1 diabetes. Diabet. Med. 27, 480–484 (2010).
Wang, Y., Dassau, E. & Doyle, F. J. 3rd. Closed-loop control of artificial pancreatic Beta -cell in type 1 diabetes mellitus using model predictive iterative learning control. IEEE Trans. Biomed. Eng. 57, 211–219 (2010).
Camacho, E. F. & Bordons, C. Model Predictive Control (Springer-Verlag, London, 1999).
Cobelli, C. et al. Diabetes: Models, signals, and control. IEEE Rev. Biomed. Eng. 2, 54–96 (2009).
Kovatchev, B., Anderson, S., Heinemann, L. & Clarke, W. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care 31, 1160–1164 (2008).
Garg, S. K. et al. Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol. Ther. 11, 65–72 (2009).
Kamath, A., Mahalingam, A. & Brauker, J. Analysis of time lags and other sources of error of the DexCom SEVEN continuous glucose monitor. Diabetes Technol. Ther. 11, 689–695 (2009).
Weinstein, R. L. et al. Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care 30, 1125–1130 (2007).
Garg, S. K., Voelmle, M. & Gottlieb, P. A. Time lag characterization of two continuous glucose monitoring systems. Diabetes Res. Clin. Pract. 87, 348–353 (2010).
Wei, C. et al. Measurement delay associated with the Guardian RT continuous glucose monitoring system. Diabet. Med. 27, 117–122 (2010).
Keenan, D. B., Mastrototaro, J. J., Voskanyan, G. & Steil, G. M. Delays in minimally invasive continuous glucose monitoring devices: a review of current technology. J. Diabetes Sci. Technol. 3, 1207–1214 (2009).
McGarraugh, G. & Bergenstal, R. Detection of hypoglycemia with continuous interstitial and traditional blood glucose monitoring using the FreeStyle Navigator Continuous Glucose Monitoring System. Diabetes Technol. Ther. 11, 145–150 (2009).
Wilinska, M. E. et al. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies. J. Diabetes Sci. Technol. 3, 1109–1120 (2009).
El-Khatib, F. H., Russell, S. J., Nathan, D. M., Sutherlin, R. G. & Damiano, E. R. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci. Transl. Med. 2, 27ra27 (2010).
Heinemann, L. Variability of insulin absorption and insulin action. Diabetes Technol. Ther. 4, 673–682 (2002).
Carroll, M. F. & Schade, D. S. The dawn phenomenon revisited: implications for diabetes therapy. Endocr. Pract. 11, 55–64 (2005).
Riazi, A., Pickup, J. & Bradley, C. Daily stress and glycaemic control in type 1 diabetes: individual differences in magnitude, direction, and timing of stress-reactivity. Diabetes Res. Clin. Pract. 66, 237–244 (2004).
Turner, B. C., Jenkins, E., Kerr, D., Sherwin, R. S. & Cavan, D. A. The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. Diabetes Care 24, 1888–1893 (2001).
Szypowska, A. et al. Age-dependent basal insulin patterns in children with type 1 diabetes treated with continuous subcutaneous insulin infusion. Acta Paediatr. 98, 523–526 (2009).
Davidson, P. C., Hebblewhite, H. R., Steed, R. D. & Bode, B. W. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr. Pract. 14, 1095–1101 (2008).
Steil, G. M., Rebrin, K., Darwin, C., Hariri, F. & Saad, M. F. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 55, 3344–3350 (2006).
Dassau, E., Bequette, B. W., Buckingham, B. A. & Doyle, F. J. 3rd. Detection of a meal using continuous glucose monitoring: implications for an artificial beta-cell. Diabetes Care 31, 295–300 (2008).
Kovatchev, B. et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J. Diabetes Sci. Technol. 4, 1374–1381 (2010).
Weinzimer, S. A. et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 31, 934–939 (2008).
Palerm, C. C. et al. Closed-loop insulin delivery utilizing insulin feedback: preliminary clinical results. J. Diabetes Sci. Technol. 3, a124 (2009).
[No authors listed] Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am. J. Med. 90, 450–459 (1991).
Tsalikian, E. et al. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care 29, 2200–2204 (2006).
McMahon, S. K. et al. Glucose requirements to maintain euglycemia after moderate-intensity afternoon exercise in adolescents with type 1 diabetes are increased in a biphasic manner. J. Clin. Endocrinol. Metab. 92, 963–968 (2007).
Tsalikian, E. et al. Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus. J. Pediatr. 147, 528–534 (2005).
Bussau, V. A., Ferreira, L. D., Jones, T. W. & Fournier, P. A. A 10-s sprint performed prior to moderate-intensity exercise prevents early post-exercise fall in glycaemia in individuals with type 1 diabetes. Diabetologia 50, 1815–1818 (2007).
Sigal, R. J. et al. Hyperinsulinemia prevents prolonged hyperglycemia after intense exercise in insulin-dependent diabetic subjects. J. Clin. Endocrinol. Metab. 79, 1049–1057 (1994).
Breton, M. D. Physical activity—the major unaccounted impediment to closed loop control. J. Diabetes Sci. Technol. 2, 169–174 (2008).
Renard, E., Place, J., Cantwell, M., Chevassus, H. & Palerm, C. C. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. Diabetes Care 33, 121–127 (2010).
Kovatchev, B. P. et al. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 21, 1870–1875 (1998).
Hill, N. R. et al. A method for assessing quality of control from glucose profiles. Diabet. Med. 24, 753–758 (2007).
Rodbard, D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol. Ther. 11 (Suppl. 1), S55–S67 (2009).
Cryer, P. E. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr. Pract. 14, 750–756 (2008).
Weller, C., Linder, M., Macaulay, A., Ferrari, A. & Kessler, G. Continuous in vivo determination of blood glucose in human subjects. Ann. NY Acad. Sci. 87, 658–668 (1960).
Clemens, A. H., Chang, P. H. & Myers, R. W. The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS). Horm. Metab. Res. Suppl. 7, 23–33 (1977).
Pfeiffer, E. F., Thum, C. & Clemens, A. H. The artificial beta cell—a continuous control of blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion system). Horm. Metab. Res. 6, 339–342 (1974).
Renard, E., Costalat, G., Chevassus, H. & Bringer, J. Closed loop insulin delivery using implanted insulin pumps and sensors in type 1 diabetic patients. Diabetes Res. Clin. Pract. 74 (Suppl. 2), S173–S177 (2006).
Dassau, E. et al. Modular artificial beta-cell system: a prototype for clinical research. J. Diabetes Sci. Technol. 2, 863–872 (2008).
Voskanyan, G. et al. Closed-loop insulin delivery utilising insulin feedback: Overnight control. J. Diabetes Sci. Technol. 4, a177 (2010).
Sherr, J. L. et al. Frequency of exercise-related hypoglycemia using a closed-loop artificial pancreas: Preliminary results. J. Diabetes Sci. Technol. 4, a157 (2010).
Hovorka, R. et al. Overnight closed-loop insulin delivery in adults with type 1 diabetes: crossover randomised controlled studies. BMJ (in press).
Murphy, H. R. et al. Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes. Diabetes Care 34, 406–411 (2011).
Elleri, D. et al. Automated overnight closed-loop glucose control in young children with type 1 diabetes. Diabetes Technol. Ther. doi:10.1089/dia.2010.0176.
Buckingham, B. et al. Duration of nocturnal hypoglycemia before seizures. Diabetes Care 31, 2110–2112 (2008).
Buckingham, B. et al. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care 33, 1013–1017 (2010).
Cengiz, E. et al. Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop system. Diabetes Technol. Ther. 11, 207–210 (2009).
Davis, E. A., Keating, B., Byrne, G. C., Russell, M. & Jones, T. W. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 20, 22–25 (1997).
Sovik, O. & Thordarson, H. Dead-in-bed syndrome in young diabetic patients. Diabetes Care 22 (Suppl. 2), B40–B42 (1999).
Elleri, D. et al. Parental attitudes towards overnight closed-loop glucose control in children with type 1 diabetes. Diabetes Technol. Ther. 12, 35–39 (2010).
Panteleon, A. E., Loutseiko, M., Steil, G. M. & Rebrin, K. Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system. Diabetes 55, 1995–2000 (2006).
El-Khatib, F. H., Jiang, J. & Damiano, E. R. A feasibility study of bihormonal closed-loop blood glucose control using dual subcutaneous infusion of insulin and glucagon in ambulatory diabetic swine. J. Diabetes Sci. Technol. 3, 789–803 (2009).
Patek, S. D. et al. In silico preclinical trials: methodology and engineering guide to closed-loop control in type 1 diabetes mellitus. J. Diabetes Sci. Technol. 3, 269–282 (2009).
Chassin, L. J., Wilinska, M. E. & Hovorka, R. Evaluation of glucose controllers in virtual environment: methodology and sample application. Artif. Intell. Med. 32, 171–181 (2004).
Wilinska, M. E. & Hovorka, R. Simulation models for in silico testing of closed-loop glucose controllers in type 1 diabetes. Drug Discov. Today Dis. Models 5, 289–298 (2008).
Wilinska, M. E. et al. Simulation environment to evaluate closed-loop insulin delivery systems in type 1 diabetes. J. Diabetes Sci. Technol. 4, 132–144 (2010).
Hovorka, R. et al. Closing the loop: the adicol experience. Diabetes Technol. Ther. 6, 307–318 (2004).
Chan, A., Breton, M. D. & Kovatchev, B. P. Effects of pulsatile subcutaneous injections of insulin lispro on plasma insulin concentration levels. J. Diabetes Sci. Technol. 2, 844–852 (2008).
Man, C. D., Breton, M. D. & Cobelli, C. Physical activity into the meal glucose-insulin model of type 1 diabetes: in silico studies. J. Diabetes Sci. Technol. 3, 56–67 (2009).
Kovatchev, B. P., Breton, M., Dalla Man, C. & Cobelli, C. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J. Diabetes Sci. Technol. 3, 44–55 (2009).
Basu, R. et al. Effects of age and sex on postprandial glucose metabolism: differences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes 55, 2001–2014 (2006).
Hovorka, R. et al. Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT. Am. J. Physiol. 282, E992–E1007 (2002).
Hovorka, R., Chassin, L. J., Ellmerer, M., Plank, J. & Wilinska, M. E. A simulation model of glucose regulation in the critically ill. Physiol. Meas. 29, 959–978 (2008).
Kanderian, S. S., Weinzimer, S., Voskanyan, G. & Steil, G. M. Identification of intraday metabolic profiles during closed-loop glucose control in individuals with type 1 diabetes. J. Diabetes Sci. Technol. 3, 1047–1057 (2009).
Elleri, D. et al. Absorption of an evening meal with complex carbohydrates in type 1 diabetes. Diabetes 50 (Suppl. 1), a422 (2010).
Capani, F. et al. Insulin requirement of simple and complex carbohydrate foods in type 1 (insulin-dependent) CSII-treated diabetic subjects, obtained by biostator. Correlation with glycaemic index. Acta Diabetol. Lat. 28, 47–53 (1991).
Klonoff, D. C. The need for a glycemia modeling comparison workshop to facilitate development of an artificial pancreas. J. Diabetes Sci. Technol. 4, 1–3 (2010).
Kowalski, A. J. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol. Ther. 11 (Suppl. 1), S113–S119 (2009).
Pinkos, A. et al. FDA's proactive role in the development of an artificial pancreas for the treatment of diabetes mellitus. Drug Discov. Today Technol. 4, 25–28 (2007).
Vaughn, D. E. et al. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol. Ther. 11, 345–352 (2009).
Steiner, S. et al. A novel insulin formulation with a more rapid onset of action. Diabetologia 51, 1602–1606 (2008).
Raz, I. et al. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin. Ther. 31, 980–987 (2009).
Pettis, R. J. et al. Intradermal injection of regular or lispro insulin with microneedles provides faster insulin uptake and postprandial glycemic benefit. J. Diabetes Sci. Technol. 4, a127 (2010).
Liebl, A. et al. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion. Diabetes Obes. Metab. 11, 1001–1008 (2009).
Weyer, C. et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care 26, 3074–3079 (2003).
Lindpointner, S. et al. Use of the site of subcutaneous insulin administration for the measurement of glucose in patients with type 1 diabetes. Diabetes Care 33, 595–601 (2010).
Bergenstal, R. M. et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N. Engl. J. Med. 363, 311–320 (2010).
Ritholz, M. D. et al. Psychosocial factors associated with use of continuous glucose monitoring. Diabet. Med. 27, 1060–1065 (2010).
Ritholz, M. D. et al. Perceptions of psychosocial factors and the insulin pump. Diabetes Care 30, 549–554 (2007).
Acknowledgements
R. Hovorka is supported by grants from the Juvenile Diabetes Research Foundation (#22-2006-1113, #22-2007-1801, #22-2009-801), Diabetes UK (BDA07/0003549, BDA07/0003551), European Commission Framework Program 7 (247138), the NIH (DK085621) and the NIHR Cambridge Biomedical Research Centre.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares associations with the following companies/organizations: Abbott Diabetes Care (grant/research support), Animas (grant/research support, consultant, speaker), Lifescan (speaker), Medtronic (speaker), University of Cambridge (patent holder).
Rights and permissions
About this article
Cite this article
Hovorka, R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 7, 385–395 (2011). https://doi.org/10.1038/nrendo.2011.32
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2011.32
This article is cited by
-
Recent advances in the precision control strategy of artificial pancreas
Medical & Biological Engineering & Computing (2024)
-
Semi-Implantable Bioelectronics
Nano-Micro Letters (2022)
-
A closed-loop healthcare processing approach based on deep reinforcement learning
Multimedia Tools and Applications (2022)
-
Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial
Nature Medicine (2021)
-
A boronate gel-based synthetic platform for closed-loop insulin delivery systems
Polymer Journal (2021)